Featured Articles

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) as a single-agent therapy for adults…
Read More...

Merck, known as MSD outside the U.S. and Canada, has entered into a $700 million funding agreement with Blackstone Life Sciences to support the development of sacituzumab tirumotecan…
Read More...

Eli Lilly and Company has announced plans to invest $3 billion in a new state-of-the-art manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park.…
Read More...

UCB, a global biopharmaceutical company, has received U.S. Food and Drug Administration (FDA) approval for KYGEVVI, a treatment for adults and pediatric patients suffering from…
Read More...

Novo Nordisk has confirmed submitting an unsolicited proposal to acquire U.S.-based Metsera, Inc., a biotechnology company developing early- and mid-stage incretin and non-incretin…
Read More...

Alexion, AstraZeneca Rare Disease, announced that the European Commission has approved Koselugo (selumetinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN)…
Read More...

Novartis announced that it has successfully completed the acquisition of Tourmaline Bio, Inc., making the biotechnology company an indirect wholly owned subsidiary of Novartis.…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of WINREVAIR™ (sotatercept-csrk) for the…
Read More...

GSK plc has entered into an agreement with Syndivia, a private biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), granting GSK exclusive worldwide…
Read More...

Ipsen has announced plans to acquire ImCheck Therapeutics, a private French biotechnology company developing next-generation immuno-oncology treatments, in a deal that expands Ipsen’s…
Read More...

Takeda Pharmaceutical Company has entered a license and collaboration agreement with Innovent Biologics to develop, manufacture and commercialize two late-stage oncology medicines —…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

Novo Nordisk and Omeros Corporation have entered into a definitive agreement granting Novo Nordisk exclusive global rights to zaltenibart (formerly OMS906), a clinical-stage antibody…
Read More...

BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics in a cash-and-stock deal valued at approximately $700 million, aiming to expand its portfolio of treatments for…
Read More...

Pfizer Inc. announced positive topline results from its Phase 3 HER2CLIMB-05 trial, marking a potential breakthrough in first-line treatment for patients with HER2-positive (HER2+)…
Read More...

Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration (FDA) for its new oral therapy, JASCAYD (nerandomilast), for the treatment of idiopathic pulmonary…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals' Libtayo® (cemiplimab-rwlc) as the first adjuvant immunotherapy for adult patients with cutaneous…
Read More...

Algen Biotechnologies has entered a multi-target partnership with AstraZeneca aimed at speeding up the discovery of new therapeutic targets in immunology. The collaboration will…
Read More...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a promising anti-microtubule binding region-tau…
Read More...

Pfizer has announced a historic agreement with the Trump Administration aimed at significantly reducing prescription drug prices for American patients while reinforcing the U.S.'s…
Read More...